macromolecules Flashcards

1
Q

Why do proteins undergo degradation?

A
  • Different lifespan across proteins
    • Structural tend to have longer lifespans (low turnover)
    • (most) Regulatory tend to have shorter lifespans
  • To ensure proper regulation of cell signalling pathways through maintaining normal protein turnovers
  • To remove misfolded (no native conformation) and damaged (eg. oxidised) proteins that can lead to abnormal cellular activities
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What if proteins cannot undergo degradation?

A

If no degradation —> accumulation of toxicity —> body cannot function properly —> disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what is an example of the consequences of a protein not being able to undergo degradation?

A

Short-lived protein: Hypoxia inducible factor 1 alpha (HIF-1 alpha)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what normally happens to HIF-1 alpha in normoxia conditions?

A
  • A transcription factor that is produced during hypoxia (insuff O2 in tissues for adequate homeostasis) to maintain oxygen homeostasis
    • MOA: Induces expression of genes involved in angiogenesis (form new blood vessels), cell migration, glycolytic (glucose is broken down to form pyruvate) pathway
  • In normoxia (normal O2 levels), HIF-1 alpha maintained at low levels (negligible) as not needed —> so half life is only 5-8 mins
  • Short half-life due to prolyhydroxylases, which is only active when there is O2 (normoxia) —> hydroxylated HIF-1 alpha —> recognised and targeted for ubiquitination —>
  • Ubiquitinated HIF-1 alpha degraded by 26S proteasome (aka degraded by ubiquitin-proteasome system)
    • pVHL: Part of the ubiquitin-proteasome system that recognises HIF-1 alpha (which is a substrate of pVHL) —> HIF-1 alpha gets ubiquitinated —> Proteasomal degradation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

what if HIF-1 alpha cannot be degraded?

A
  • If HIF-1 alpha cannot be degraded —> Von Hipel-Lindau (VHL) disease
    • Mutated pVHL —> Cannot degrade HIF-1 alpha —> HIF-1 alpha accumulates (so this happens despite being in normoxia) —> increase in HIF-1 alpha transcriptional activity —> increase expression of target genes: Increase matrix metalloproteinases (MMPs: enzymes that encourage cell migration and invasion), increase vascular endothelial growth factor (VEGF: promote angiogenesis) —> increase invasion, metastasis (spread of cancer cells), angiogenesis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

what are the clinical outcomes if HIF-1 alpha cannot be degraded?

A
  • Clinical outcomes: Tumour like pheochromocytomas, hemangioblastomas of CNS, clear-cell renal carcinomas, retinal capillary angiomas ] all have high degrees of vascularisation due to angiogenesis and high HIF-1 alpha transcriptional activity 😖
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

why does healthy HIF-1 alpha have a short half life?

A

Short half-life due to prolyhydroxylases, which is only active when there is O2 (normoxia) —> hydroxylate two proline residues (Pro402 and Pro564) in HIF-1 alpha —> hydroxylated HIF-1 alpha —> recognised and targeted for ubiquitination

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what is VHL?

A
  • VHL: Heriditary disease, caused by autosomal dominant mutation in one of the alleles of gene VHL which encodes for VHL protein (aka pVHL)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

what are the Types of protein degradation in mammalian cells?

A
  1. Proteasomal degradation (80-90%)
  2. Lysosomal degradation

note: Therapeutic proteins (from drugs) will also get degraded by either pathways —> Either identified as alien (since exogenous and taken up by lysosomes) or recombinant protein (eg. recombinant insulin and taken up by proteasome)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

who is proteasomal degradation for?

A
  • Normally for ubiquitinated proteins (exceptions for very small minority)
  • By 26S proteasome
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

who is lysosomal degradation for?

A

Only for membrane-associated proteins and alien proteins (extracellular proteins) —> internalised into a vesicle in lysosomes by endocytosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

which degradation type is a specific process?

A

proteasomal degradation!
Specific process: Unique for each protein

lysosomal degradation: Not specific: Will be degraded regardless of identity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

how does lysosomal degradation occur?

A

When proteins enter lysosomes that has acidic interior of pH 4.5 —> proteolysis occurs (cleavage of peptide bond)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what is the Structure of Proteasome?

A
  • Very huge cylindrical (core is hollow) protein in cells
  • Consist of min 33 subunits, with total molecular weight ~2.5MDa
  • Major proteasome: 26S proteasome
    • Found in all cells
    • Degrades and removes regulatory proteins
    • Composed of a 20S core particle: Capped by a 19S regulatory particle at lid and base
      • 20S core particle is made up of 4 heptameric rings assembled to form cylindrical structure —> 2 outer rings = 2 alpha subunits AND 2 inner rings = 2 beta subunits
      • Inner rings contain proteolytic active sites
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

how is proteasomal degradation a Selective process?

A
  • Narrow entry into 20S core particle for selectivity
  • Partially unfolded proteins need to assume a primary polypeptide chain to fit through —> Upon entry, will totally unfold to stretch along channel to reach/ be translocated to inner rings —> Gets hydrolysed to short peptides of 3-25AA —> released from opposite end of channel
  • 19S regulatory particles contain ATPase subunits to gate entrance, remove Ub, unfold and transfer unfolded protein to chamber
  • Gate normally closed
  • Only allows ubiquitinated proteins into channel
    • But ubiquitin is a very small molecule, so need multiple of it to act as a tag on protein to be recognised by proteasome —> Polyubiquitin chain (min 4 ubiquitin molecules that is linked through Lys48)
    • Prior to entry, deubiquitinating enzymes (DUBs) will cleave tag into monomers
    • Monomers escape proteasome into cytoplasm and are recycled to tag other protein substrate
    • Proteasome engages protein substrate —> Polypeptide unfolds to enter and gets translocated into 20S core to be degraded
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is ubiquitin (Ub)?

A
  • Peptide, only has 76 residues with high lysine content of 7Lys
  • Amino group of Lys gets utilised to form polyubiquitin chain to be attached to protein substrate
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

what is Monoubiquitination?

A
  • Attachment of one Ub to protein
  • Not targeted for degradation
  • Post-translational modification event: Activated or not to carry out cellular function
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

what is an example of monoubiquitination?

A
  • Monoubiquitination of histones and transcription factors to allow activation of transcription
  • Monoubiquitination of surface cell receptors to activate them to participate in endocytosis and degradation in lysosomes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

what are the Types of ways that protein substrates reach proteasome?

A
  • Close proximity: Substrates bind directly to proteasome by interacting with 19S regulatory particle subunits (which can recognise ubiquitin tag)
  • Substrates brought to proteasome by adaptor proteins that bind to both proteasome and polyubiquitin chain
  • Minority: Substrates gets degraded without being ubiquitinated
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

what are the Types of endocytosis?

A
  1. Phagocytosis (cell eating)
  2. Pinocytosis (cell drinking)
  3. Receptor-mediated endocytosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

what is endocytosis: Phagocytosis (cell eating) under lysosomal degradation?

A
  • By cytotoxic T cells, innate immunity (eg. macrophages)
  • Substance is quite big: Cell debris, dead cells, protein aggregates, pathogenic microorganisms, dust particles, particulate non-living matter
  • Membrane bound upon being eaten up
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

what is endocytosis: Pinocytosis (cell drinking) under lysosomal degradation?

A
  • Substance is extracellular fluid
  • Non specific as applies for any solutes that are dissolved in extracellular fluid
23
Q

what is endocytosis: Receptor-mediated endocytosis under lysosomal degradation?

A
  • Substance is ligands that are recognised by receptors expressed on cell membrane —> Bind —> Folding up of plasma membrane which internalises both receptor and ligands into the vesicles —> Coated vesicles fuse with endosomes intracellularly —> Contents in endosomes are sent to lysosomes for degradation or recycles to plasma membrane
  • Eg. Insulin, cytokines, hormones, proteins, metabolites
24
Q

what are Biopharmaceutical products?

A
  • Macromolecules
  • Mainly protein products: Recombinant proteins, monoclonal antibodies, nucleic acid-based products etc
25
Q

compare between traditional chemical-based drugs and biopharmaceutical products/ biologics

A
  • Traditional chemical-based drugs —> More artificial
    • Molecular weight: Smaller, <1000Da
    • Can be chemically synthesised and purified to homogeneity
    • Can chemically modify to enhance activity
    • Off-target effects due to small size
  • Biopharmaceutical products/ biologics —> increasingly prescribed as it is more natural (protein-based)
    • Molecular weight: Larger, thousands of Da
    • Not easily characterised and refined to high degree of purity due to polypeptide complexity —> So derive from living sources
    • Modifications in amino acid residues —> Same name still used
    • More predictable and lesser side effects
26
Q

what are the Challenges of Biopharmaceutical products?

A
  • Immunogenicity*: Due to deriving non-human proteins —> Might not be properly purified
  • Proteins are susceptible to denaturing and protease degradation in biological fluids (in extracellular fluids) upon administration due to interaction with body’s defence system
    • MW of proteins > 200kDaltons (outlier, quite rare) —> undergoes phagocytosis as too large so want to kill it
  • Proteins are susceptible to degradation by intracellular degradation systems
  • Distribution of proteins (macromolecules) to tissues is limited by varying permeability (porosity) of vasculatures (blood and lymphatic vessels) across patients
27
Q

what kind of absorption property do macromolecules like proteins have ?

A

Poor oral systematic absorption oral F ~2%

28
Q

why do macromolecules have poor oral systemic absorption?

A
  • Poor protein stability —> Get degraded (eg. acidity of gastric fluids, digestive enzymes)
  • Poor permeability (mucus layer lining entire GIT, intestinal epithelial overall carry -ve charge + tight junctions exist between mucosal epithelial cells restrict absorption of hydrophilic peptides/ proteins)
  • Mucosal epithelial are also present in respiratory, digestive, urinary, reproductive tract
    • Have immune cells of innate immunity —> Ready to attack —> Degrade proteins
29
Q

whats the solution for targeting the problem of macromolecules having poor oral systemic absorption?

A
  • SC or IM administration —> Bloodstream
    • SC: Upon delivery to hypodermis/ subcutaneous tissues (made of adipose tissue, network of extracellular matrix (ECM), nerves (thus feel pain), blood capillaries) —> Proteins diffuse and convect through ECM (elderly: loose ECM so quick) to reach blood or lymphatic capillaries
30
Q

what are the methods of subcutaneous admin of macromolecules into the bloodstream?

A

Diffusion
Convection

31
Q

how does diffusion occur?

A
  • Movement of single/ smaller particles
  • High to low conc (slow down after awhile as equilibrium is established)
  • Enters blood cap directly
  • Inversely related to MW of proteins (easier for small proteins to diffuse) —> Limited for large proteins
32
Q

how does convection work?

A
  • Movement of large mass of particles in fluid
  • Enters lymphatic cap first before going into blood cap
  • Not so limited by MW unless really very enormous and get trapped in ECM
  • Limited by steric hinderance and charge interactions
33
Q

whats the molecular weight of proteins and how does this affect absorption?

A
  • Larger proteins: >16-20kDa (mAb)
    • Diffusion slow so absorption due to convection —> Enter larger lymphatic capillaries (blood cap too small) —> Drain into lymph nodes (has T cells, B cells which can attack proteins)
  • Smaller proteins: <16-20kDa (Eg. insulin, cytokines)
    • Absorption mostly due to diffusion, can be via circulatory and lymphatic systems
    • Perfusion (blood flow throughout tissue) influence capillary absorption
34
Q

what are the Rate limiting factors that can change absorption rates of proteins (could be due to diseases or demographics)?

A
  • Interstitial fluid transport rate
  • Lymphatic transport rate —> Due to disease where fluids trapped in lymphatic cap
35
Q

how is the distribution like for macromolecules?

A

Protein drugs can be unbounded or bounded in circulation

  • Binding: Normally binds to plasma proteins (albumin found in blood) —> Improves circulation half-life —> more efficient delivery to target tissues
    • Albumin is quite large
  • Unbound: Can attract attention of immune cells —> Destroyed!!
36
Q

how do proteins move in the body?

A
  • Movement from circulation —> Interstitial fluid of tissues —> Tissues or vice versa
  • Movement is across or between endothelial cells
  • Passive movement is via convection or diffusion
37
Q

is there an instrument that reps how proteins move in the body?

A
  • Two pore model
    • Characterise tissue level protein disposition
    • Endosomal space: Rep porous tissue microvascular endothelium aka blood cap endothelial wall
      • Has small and large pores
      • Passive movement: Small proteins can pass through both, large proteins only large to gain entry to interstitial space from plasma space
      • J is convection, PS is diffusion
38
Q

how are proteins metabolised?

A
  • Metabolism of protein drugs is by proteolysis by proteolytic enzymes
    • ECF contains proteases, immune cells ready to perform phagocytosis and proteolysis
    • Can happen in (i) interstitial fluids (aka ECF), (ii) on cell surfaces, (iii) intracellularly via lysosomal (non-protein specific) or proteasomal (protein specific) degradation
39
Q

are proteins metabolised by the liver?

A

No metabolism of protein by liver

40
Q

what is FcRn?

A

Neonatal Fc receptor

FcRn is an ADDITIONAL (dk if part of the 6) lg-binding Fc receptor,

where there are 6 normal lgG-binding Fc receptors on effector cells for Fc of lg to bind to —> activate effector cells

imagine:
effector cell has Fc receptors x6 that can bind to lg to activate effector cells
sudd effector cells has an additional receptor called FcRn

41
Q

what is a characteristic of FcRn?

A

FcRn is structurally similar to MHC Class I (which recognises endogenous antibodies)

FcRn has separate binding sites for lgG and serum albumin (produced by liver) —> can bind simultaneously

42
Q

how was FcRn discovered?

A

during preggo

FcRn was found to be responsible for transport of maternal lgG (i) across placenta to foetus and (ii) from milk across intestines of newborn babies

43
Q

what is the function of FcRn?

A
  1. Regulates lg turnover* (lg homeostasis) and activates effector cells when FcRn expressed on effector cells binds to Fc receptor on lgG
  2. Involved in the recycling of antibodies and serum albumin
44
Q

where is FcRn expressed?

A

FcRn receptor is expressed in a wide range of cell types, eg. endothelial and epithelial cells

45
Q

how does FcRn help in the recycling of antibodies and serum albumin in ENDOTHELIAL CELLS?

A

note: endothelial cells (aka blood cap cells)

  1. In bloodstream (pH 7.4): Contains dissolved (and hence soluble) endogenous lgG and albumin —> Taken up by endothelial cells by pinocytosis (cell drinking) to form endosomes (pH 5-6) that contains FcRn
  2. Acidic pH in endosomes causes binding of albumin and lgG to FcRn —> FcRn-albumin complex
  3. Complex can be recycled to cell surface —> Release (exocytosis) albumin and lgG as free entities, FcRn re-expressed on cell surface of endothelial cell again —> Lengthens circulation half life of lgG antibody & albumin
46
Q

how does FcRn help in the recycling of antibodies and serum albumin in EPITHELIAL CELLS?

A

note: epithelial cells (in GIT) —> Idea for delivery by oral route

  • 3 small squares illustrate the tight junctions
  • Express FcRn receptor at apical end (facing intestinal contents) which is acidic —> allows FcRn receptor to bind to free lgG and albumin —> taken up by epithelial cells —> house in acidic endosomes —>
  • Transcytosis occurs whereby endosomes crosses to fuse with basolacteral side (face bloodstream) —> exposure to neutral pH causes FcRn to dissociate from albumin and lgG —> free albumin and lgG released into interstitial (bloodstream)
47
Q

how are proteins eliminated?

A
  • Proteolytic degradation
  • Renal excretion: Glomerular filtration
48
Q

what are the factors affecting elimination of proteins?

A
  • Proteins >50kDa cannot be renally eliminated as too big to get filtered
  • Net positive charged proteins have higher renal filtration for the same size, since glomerular basement membrane carries neg charges
  • Shape and rigidity of protein
  • Tubular reabsorption: Pos charge proteins gets reabsorbed more as tubular epithelial have net neg charge (abit contradictory with point 2, but need to see net loss)
49
Q

what are the strategies to improve pk of protein therapeutics?

A
  1. Glycosylation of proteins
  2. PEGlyation of proteins
  3. Increase in size (MW) via fusion proteins
50
Q

what happens if protein cannot be filtered?

A

Technically if protein cannot be filtered, will be recirculated back into bloodstream —> Half life lengthened

51
Q

what is glycosylation of proteins in helping to improve its PK?

A
  • Addition of glycan groups (carbohydrates) to protein
    • Types of glycan groups can vary and hence affect activity: straight vs branched chain, size, position of attached in AA seq of protein
  • MOA: N-linked glycosylation of proteins —> Increase size —> increase half-life or modify binding to glycoprotein receptors
52
Q

how can glycosylation of proteins help in improving its PK?

A
  • Glycoengineering can occur in antibodies: Double-edged sword (this portion abit confusing but im sick)
    • Human lgGs contain N-linked glycans —> remove fucose attached to Asn297 (defucosylated, refer to IC5) —> improve affinity of binding of Fc in lgG to Fc receptor 😄
    • Want mannose glycans to be high in content in Fc —> to be more recognised by mannose receptor —> trigger innate immunity to rapidly remove antibodies —> shorten half life 😖
53
Q

how can PEGlyation of proteins help in improving its PK?

A
  • Polymer with lots of hydroxyl groups —> make water-compatible —> conjugate to protein drugs —> increase size >50kDa to not be filtered —> lengthen half life
  • Decrease elimination by proteolysis due to formation of protective layer upon conjugation —> shield from immune cells and proteolytic enzymes —> reduced immunogenicity
54
Q

how can Increasing size (MW) via fusion proteins help in improving its PK?

A
  • Fc domain of antibody or albumin gets bound to FcRn —> Increase circulation half life
    • Eg. Etanercept
    • Note albumin has many binding pockets —> bind to fatty acids, drugs, proteins —> competition —> compromise FcRn binding and hence recycling —> hence experimental strategy